Please assess the completion status of the following clinical trial:

Trial Title: GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Have provided written and signed informed consent;~2. Histologically confirmed invasive ductal carcinoma;~3. Planned to received (neo)/adjuvant chemotherapy;~4. Eastern Cooperative Oncology Group (ECOG) score of 0 to 1;~5. Can cope with HVLT-RDR and ADAS-Cog evaluation;~6. No prior therapy could induce neurological damage,within 4 weeks~7. Normal blood routine, liver and kidney functions within 1 week before enrollment in this study;~8. Women of childbearing age have a negative serum or urinary pregnancy tests prior to enrollment in this study; Pre-menopause women are contracepted with medically acceptable methods during the study period.~9. Compliance with the study protocol.~Exclusion Criteria:~1. Eastern Cooperative Oncology Group (ECOG) score ≥ 2;~2. Hypersensitivity to experiment agents or components;~3. Women with pregnancy or breast feeding;~4. A clear past history of neurological or psychiatric disorders, including epilepsy or dementia;~5. Abnormal baseline impairment of cognitive impairment;~6. Poor compliance, unwillingness or inability to follow protocol to continue the study;~7. Any circumstances in which the investigator deemed the subject unsuitable for enrollment in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- experimental group (Type: EXPERIMENTAL): standard (neo)adjuvant chemotherapy plus Ganglioside-Monosialic Acid 100mg+250ml normal saline (NS)
- Control group (Type: OTHER): standard (neo)adjuvant chemotherapy plus 250ml normal saline (NS)

Based on this trial design, predict the completion outcome and termination type (if applicable).